Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics Inc (NQ: PTGX )

41.11 +0.07 (+0.17%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Protagonist Therapeutics Inc

< Previous 1 2 3 4 5 6 7 8 Next >
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Dick's Sporting Goods, WW International, Sea Limited And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping around 150 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Why Protagonist Therapeutics Shares Are Trading Higher Today
Via Benzinga
Top 5 Health Care Stocks That May Collapse In February
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Protagonist Therapeutics Earnings Perspective: Return On Capital Employed
Protagonist Therapeutics (NASDAQ:PTGX) brought in sales totaling $859 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 96.07%, resulting in a loss of $41.04... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low. 
Via Benzinga
Why Protagonist Therapeutics Shares Are Crashing Today
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) stock rose 14.5% to $0.53 during Tuesday's after-market session. The company's market cap stands at $14.0 million. 
Via Benzinga
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shareholder Alert: Investigation over Possible Wrongdoing
San Diego, CA -- (SBWIRE) -- 06/27/2022 -- Certain directors of Protagonist Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties. 
Via SBWire
3 Biotech Stocks to Buy Before They Boom
It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations. 
Via InvestorPlace
The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support. 
Via Benzinga
7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years
Finding micro-cap stocks to buy requires a bit of everything, including patience. Today's plan is to pick from the top of the IWC ETF. 
Via InvestorPlace
Investigation Reminder: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
Investigation Alert: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
71 Biggest Movers From Yesterday
Gainers Evoke Pharma, Inc. (NASDAQ: EVOK) shares jumped 118.5% to close at $0.86 on Tuesday. The FDA granted new drug product exclusivity to Evoke Pharma's Gimoti (... 
Via Benzinga
Mid-Afternoon Market Update: Crude Oil Rises Over 3%; Protagonist Therapeutics Shares Plummet
U.S. stocks remained lower toward the end of trading, with the Dow Jones tumbling more than 500 points on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Stocks Flounder As Wall Street Rotates Out Of Tech
Big Tech stocks are struggling ahead of several key earnings reports. 
Via Talk Markets
Mid-Day Market Update: Nasdaq Down 400 Points; Arch Resources Shares Jump
U.S. stocks extended losses midway through trading, with the Nasdaq Composite dropping 400 points on Tuesday. 
Via Benzinga
34 Stocks Moving In Tuesday's Mid-Day Session
Gainers Avadel Pharmaceuticals plc. (NASDAQ: AVDL) shares gained 36.3% to $5.74. Shares closed down 36% on Monday, seemingly on no news. Avadel issued a press release Tuesday... 
Via Benzinga
The Daily Biotech Pulse - Tuesday, April,26
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Talk Markets
Futures Slide Ahead Of Tech Earnings Deluge
Markets in general are preoccupied by the prospect of tighter monetary policy conditions from global central banks to stem rising prices. 
Via Talk Markets
Mid-Morning Market Update: Markets Open Lower; Dow Dips 300 Points
U.S. stocks traded lower this morning, with the Dow Jones dropping around 300 points on Tuesday. 
Via Benzinga
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
18 Stocks Moving in Tuesday's Pre-Market Session
Gainers Q&K International Group Limited (NASDAQ: QK) shares rose 59.2% to $1.56 in pre-market trading after dropping around 5% on Monday. Agile Therapeutics, Inc. (NASDAQ:... 
Via Benzinga
Protagonist Therapeutics Topline Data from Phase 2 IDEAL Study of PN-943 (450 mg BID) Miss Primary Endpoint
Protagonist Therapeutics (NASDAQ: PTGX) announced top-line results from the Phase 2 IDEAL clinical study evaluating PN-943 in patients with moderate-to-severe ulcerative colitis (UC). 
Via Benzinga
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. With Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.